- Home
- ARE vs QGEN Comparison
ARE vs QGEN Comparison
Compare ARE & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARE
- QGEN
- Stock Information
- Founded
- ARE 1994
- QGEN 1986
- Country
- ARE United States
- QGEN Netherlands
- Employees
- ARE N/A
- QGEN N/A
- Industry
- ARE Real Estate Investment Trusts
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ARE Real Estate
- QGEN Health Care
- Exchange
- ARE Nasdaq
- QGEN Nasdaq
- Market Cap
- ARE 13.2B
- QGEN 10.7B
- IPO Year
- ARE 1997
- QGEN 1996
- Fundamental
- Price
- ARE $54.08
- QGEN $44.04
- Analyst Decision
- ARE Hold
- QGEN Buy
- Analyst Count
- ARE 10
- QGEN 7
- Target Price
- ARE $93.00
- QGEN $50.68
- AVG Volume (30 Days)
- ARE 3.1M
- QGEN 1.0M
- Earning Date
- ARE 10-27-2025
- QGEN 11-04-2025
- Dividend Yield
- ARE 9.78%
- QGEN 3.42%
- EPS Growth
- ARE N/A
- QGEN 405.09
- EPS
- ARE N/A
- QGEN 1.69
- Revenue
- ARE $3,058,395,000.00
- QGEN $2,040,067,000.00
- Revenue This Year
- ARE N/A
- QGEN $7.37
- Revenue Next Year
- ARE N/A
- QGEN $5.65
- P/E Ratio
- ARE N/A
- QGEN $26.98
- Revenue Growth
- ARE N/A
- QGEN 5.15
- 52 Week Low
- ARE $53.96
- QGEN $37.63
- 52 Week High
- ARE $116.52
- QGEN $51.88
- Technical
- Relative Strength Index (RSI)
- ARE 18.68
- QGEN 30.60
- Support Level
- ARE $55.02
- QGEN $48.34
- Resistance Level
- ARE $58.70
- QGEN $49.53
- Average True Range (ATR)
- ARE 2.63
- QGEN 1.07
- MACD
- ARE -2.15
- QGEN -0.46
- Stochastic Oscillator
- ARE 0.57
- QGEN 12.32
About ARE Alexandria Real Estate Equities Inc.
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).